Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Singapore Private Equity Backs Concord's Take Off Plans

Executive Summary

Niche therapy players, backed by strong technology platforms, continue to attract rich valuations in India, the latest being the Singapore-based private equity firm Quadria Capital's investment in Concord Biotech Ltd, an Indian manufacturer of fermentation based biopharmaceutical APIs [active pharmaceutical ingredients].

You may also be interested in...



Asia Deal Watch: India’s Encube Targeted As Private Equity Interest In CDMOs Grows

Plus deals involving Y-Biologics/Pierre Fabre, Contera/Abzu, Chugai/Alebund, Catalyst/DyDo, Spergogenix/Abbiska, Nippon Gene/ERS Genomics, Simcere/Vivoryon, Dr. Reddy’s/Journey Medical and Innovent/Synaffix.

Warburg leads PE flow into Indian APIs with Laurus investment

Niche active pharmaceutical ingredient (API) players in India continue to attract private equity interest - the latest deal involving Warburg Pincus' acquisition of a minority stake in Laurus Labs for about INR5.50bn ($92m).

Evotec, Takeda Execs’ Big Picture Insights To Shape India’s R&D Push

Evotec's CEO and Takeda’s president of R&D provide insights around how India could shape its efforts to accelerate biopharma innovation. Backing the right technologies, fostering a culture to "stop losses" early on for projects that don't work and learning from China’s overhaul of its healthcare system were among the key takeaways.

Topics

Related Companies

UsernamePublicRestriction

Register

SC065606

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel